BioPharmSignal logoBioPharmSignal

Biotech News

Genenta Science Provides Update on CEO Ownership

Genenta Science (GNTA)Genenta ScienceCompany update

MILAN and NEW YORK , Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder,

Related news

GNTAGenenta Science2026-07-23 07:09 EST

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

LEGNLegend Biotech Corporation2026-07-27 10:00 EST

Legend Biotech Announces CEO Transition

View all latest news

Genenta Science

Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.

Recent company news

GNTAGenenta Science2026-07-23 07:09 EST

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

GNTAGenenta Science2026-04-23 11:00 EST

Genenta signs Definitive Agreements with Sophia High Tech

GNTAGenenta Science2026-03-27 09:00 EST

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

GNTAGenenta Science2026-03-24 07:26 EST

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Stock data

Close
1.26 USD
Market cap
51.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States